GH vs IOVA: fair value comparison
Guardant Health, Inc. and Iovance Biotherapeutics, Inc. · Updated 2026-10-19
GH has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. IOVA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, GH currently ranks higher by quality score.
| GH | IOVA | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $158.60 | $13.62 |
| 12-month range | $69.35–$187.22 | $1.81–$14.82 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #101 of 301 Healthcare | #103 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | High | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Uptrend |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: GH fair value analysis · IOVA fair value analysis